A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults
Authors:
- 26 February 2012
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (6) , 1433-1442
Abstract
Temsirolimus, a selective inhibitor of mammalian target of rapamycin, is an approved treatment for patients with advanced renal cell carcinoma (RCC). This study assessed the effect of intravenous (i.v.) temsirolimus 25 mg, the recommended dose for patients with RCC, on the corrected QT (QTc) interval. This 3-period crossover study enrolled healthy subjects. In periods 1 and 2, subjects received i.v. placebo either alone or with open-label oral moxifloxacin. In period 3, subjects received a single dose of temsirolimus 25 mg. The primary statistical objective was to estimate the effect of temsirolimus compared with placebo on change from time-matched baseline QTc at the end of infusion (0.5 h). Assay sensitivity was evaluated by the effect of moxifloxacin on change from time-matched baseline QTc compared with placebo. In total, 58 subjects were enrolled. Temsirolimus had no effect on QTc interval in the primary analysis. At 11 of 12 secondary time points, the upper bound for the temsirolimus QTc 90% confidence intervals for the time-matched change from baseline difference from placebo was P < 0.0001). No subject had a QTc interval exceeding 450 ms or a change from baseline of >30 ms. Therapeutic exposure to temsirolimus is not associated with clinically significant changes in QTc intervals in healthy adults.Keywords
This publication has 22 references indexed in Scilit:
- A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult SubjectsClinical Cancer Research, 2010
- Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical PracticeDrugs, 2010
- Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentBritish Journal of Pharmacology, 2010
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing ConsiderationsSeminars in Oncology, 2009
- Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimusCancer Chemotherapy and Pharmacology, 2008
- Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450‐Inducing Medications1The Journal of Clinical Pharmacology, 2007
- The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer TherapyClinical Cancer Research, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- The significance of QT interval in drug developmentBritish Journal of Clinical Pharmacology, 2002